Mankind Pharma to Acquire 70% Stake in Belgian CAR-T Cancer Therapy Developer for €48 Million

Indian pharmaceutical major Mankind Pharma Limited has announced the acquisition of a 70% stake in Belgium-based biotechnology company Armed Cell Therapeutics B.V. (ACTx) for €48 million, marking its strategic entry into next-generation cancer cell therapies. The investment represents an important expansion of the company’s research and development activities beyond conventional pharmaceutical formulations into advanced, innovation-driven treatments.

The acquisition will be undertaken through Mankind Pharma (Netherlands) B.V., the company’s wholly owned subsidiary. The definitive agreement was announced on October 15, 2026, following approval by Mankind Pharma’s Board of Directors.

Armed Cell Therapeutics specialises in developing advanced Chimeric Antigen Receptor T-cell (CAR-T) therapies designed to improve treatment outcomes for cancer patients. Its research pipeline includes programmes targeting non-Hodgkin lymphoma and small-cell lung cancer, two diseases requiring continued advances in treatment.

The investment brings together Mankind Pharma’s pharmaceutical manufacturing and commercial capabilities with the scientific expertise of an international biotechnology company developing advanced cell-based cancer treatments.

Mankind Pharma Invests €48 Million in Advanced Cancer Treatment Technologies

Mankind Pharma has entered into a definitive agreement to acquire a majority stake in Armed Cell Therapeutics, a biotechnology company incorporated in Belgium and engaged in developing next-generation CAR-T therapies.

Under the agreement, Mankind Pharma will invest approximately €48 million to acquire 70% ownership in ACTx through its Netherlands-based subsidiary. The investment will be made in instalments in accordance with the agreed transaction arrangements.

To support the acquisition, Mankind Pharma’s Board approved an additional investment of up to €45 million in Mankind Pharma (Netherlands) B.V. This increases the total authorised investment in the subsidiary to €50 million, including an earlier approval of €5 million.

Mankind Netherlands was established to support the development and acquisition of innovative pharmaceutical assets and strengthen the company’s participation in specialised therapeutic areas.

The acquisition represents Mankind Pharma’s entry into a segment of biotechnology that uses genetically engineered immune cells to target cancer. It also forms part of the company’s long-term strategy to develop a global pharmaceutical business supported by scientific innovation and advanced therapeutic technologies.

Armed Cell Therapeutics Develops Next-Generation CAR-T Therapies

Armed Cell Therapeutics is developing a portfolio of advanced cancer treatments based on CAR-T cell technology, an approach that modifies immune cells to recognise and attack cancer cells.

The company’s lead research programmes focus on non-Hodgkin lymphoma and small-cell lung cancer. Its development strategy seeks to address limitations associated with existing CAR-T treatments, including treatment resistance, insufficient persistence of engineered immune cells and difficulties in treating solid tumours.

ACTx is developing a new generation of engineered CAR-T cells designed to improve their ability to identify cancer cells, sustain anti-tumour activity and overcome biological mechanisms that allow tumours to resist treatment.

The company is also exploring technologies that could enable CAR-T cells to be generated directly within the patient’s body, an approach known as in vivo CAR-T cell generation.

Armed Cell Therapeutics is headquartered in Belgium, with operations in the Netherlands and research activities involving experienced scientific teams in the United States and Europe. Its research and early development activities also extend across international biotechnology networks.

The partnership with Mankind Pharma will support the company’s efforts to advance its therapeutic candidates and develop technologies intended to improve the effectiveness and durability of cancer treatment.

Understanding CAR-T Cell Therapy and Its Role in Cancer Treatment

Chimeric Antigen Receptor T-cell therapy is a form of immunotherapy that uses the patient’s immune system to identify and destroy cancer cells.

T cells are specialised white blood cells that play an important role in protecting the body against infections and abnormal cells. In conventional CAR-T treatment, these cells are collected from a patient and genetically modified in a laboratory to express a specially designed receptor.

The modified receptor enables the T cells to recognise specific proteins, known as antigens, present on the surface of certain cancer cells.

After modification and expansion in a controlled manufacturing environment, the engineered cells are administered to the patient. They can then identify and attack cancer cells carrying the targeted antigen.

CAR-T therapy has already transformed the treatment landscape for selected blood cancers, particularly certain forms of leukaemia, lymphoma and multiple myeloma.

However, the technology continues to face significant challenges. Some patients experience relapse because the engineered immune cells lose their effectiveness, fail to persist for sufficient periods or encounter cancer cells that no longer express the targeted antigen.

CAR-T treatment can also cause serious adverse reactions, including cytokine release syndrome and neurological complications. These risks require specialist medical supervision and carefully controlled treatment protocols.

The development of next-generation CAR-T therapies aims to improve treatment durability, expand applications and address limitations associated with existing therapeutic approaches.

Armed CAR-T Technology Designed to Improve Treatment Effectiveness

Armed Cell Therapeutics is developing modified CAR-T cells equipped with additional biological capabilities intended to strengthen their anti-cancer activity.

These advanced cells are engineered to carry additional therapeutic components, often described as payloads, that may help sustain immune-cell activity and improve their ability to function in challenging tumour environments.

The approach seeks to address a major limitation of conventional CAR-T therapy: the inability of some engineered immune cells to maintain effective activity after administration.

Cancer cells can develop resistance through several mechanisms, including changes in the expression of targeted antigens. ACTx is therefore exploring strategies that enable engineered T cells to recognise more than one cancer-associated antigen.

Targeting multiple antigens may reduce opportunities for cancer cells to evade immune recognition and could support more durable treatment responses.

Another important objective is improving CAR-T cell function within solid tumours. Unlike many blood cancers, solid tumours create complex biological environments that can interfere with immune-cell movement, survival and activity.

Armed CAR-T technologies are being developed to strengthen immune-cell performance in these environments and expand the potential applications of cell therapy.

These approaches remain under research and development, with their eventual clinical usefulness dependent on successful testing for safety and effectiveness.

Research Focuses on Non-Hodgkin Lymphoma and Small-Cell Lung Cancer

Armed Cell Therapeutics has identified non-Hodgkin lymphoma and small-cell lung cancer as the principal targets of its lead development programmes.

Non-Hodgkin lymphoma is a group of cancers affecting lymphocytes, the white blood cells involved in immune defence. The disease includes several subtypes that differ in their biological characteristics, progression and response to treatment.

CAR-T therapies have already demonstrated clinical benefits in certain forms of non-Hodgkin lymphoma, particularly in patients whose cancers have returned or failed to respond to earlier treatments.

Nevertheless, relapse remains a significant challenge, creating a need for treatments capable of producing deeper and longer-lasting responses.

ACTx is developing next-generation CAR-T candidates intended to improve the persistence and effectiveness of engineered immune cells in these difficult clinical settings.

Small-cell lung cancer represents another important area of research. It is an aggressive form of lung cancer associated with rapid disease progression and a high risk of recurrence.

Developing CAR-T therapy for small-cell lung cancer is particularly challenging because it involves a solid tumour rather than a cancer primarily affecting blood or immune-system cells.

The company’s research aims to overcome some of these biological challenges through advanced cell engineering and targeted immunotherapy approaches.

Successful development could expand the therapeutic applications of CAR-T technology beyond its established role in selected blood cancers.

In Vivo CAR-T Technology Could Transform Cell Therapy Manufacturing

One of the advanced approaches being explored by Armed Cell Therapeutics involves generating CAR-T cells directly inside the patient’s body.

Conventional CAR-T treatment generally requires a multistage manufacturing process. T cells are collected from the patient, genetically modified outside the body, expanded under controlled conditions and subsequently administered.

This process requires specialised facilities, complex logistics and stringent quality-control procedures. Manufacturing timelines and costs also present challenges for wider treatment availability.

In vivo CAR-T technology seeks to modify suitable immune cells directly within the patient, potentially reducing the need for some conventional laboratory manufacturing steps.

Researchers are investigating delivery technologies capable of introducing genetic instructions into targeted immune cells inside the body.

The objective is to enable these cells to acquire cancer-recognising capabilities and participate in anti-tumour immune responses.

If successfully developed, such approaches could simplify selected aspects of CAR-T treatment and potentially improve manufacturing scalability.

However, in vivo cell engineering presents important scientific and safety challenges, including accurate targeting of immune cells, control of genetic modification and management of unintended immune responses.

ACTx’s participation in this emerging field demonstrates its focus on technologies that could influence the next generation of personalised cancer treatment.

Experienced International Scientists Lead Armed Cell Therapeutics

Armed Cell Therapeutics was founded by a group of scientists and biotechnology professionals with extensive experience in pharmaceutical research, cell therapy and biotechnology company development.

The company’s leadership includes Dr Paul Stoffels, Chairman of the Board, who previously served as Chief Scientific Officer of Johnson & Johnson and Chief Executive Officer of Galapagos.

Dr John Mellors serves as Chief Scientific Officer. He is a Distinguished Professor of Medicine at the University of Pittsburgh and has held senior research leadership positions in biotechnology.

Peter Verhaeghe, another founder, has extensive experience in biotechnology corporate development and previously served as Chairman of argenx.

The company’s scientific and development activities draw upon expertise from research institutions and biotechnology organisations in the United States and Europe.

This international research network provides Mankind Pharma with access to experienced teams working on advanced immunotherapy technologies, specialised cell engineering and innovative cancer treatment platforms.

The acquisition also creates opportunities for collaboration across pharmaceutical research, clinical development and future commercialisation activities.

Mankind Pharma Expands Its Global Research and Innovation Strategy

Mankind Pharma has developed a major presence in India’s pharmaceutical industry through its extensive portfolio of prescription medicines, consumer healthcare products and specialised therapies.

The company operates across therapeutic segments including cardiovascular diseases, diabetes, gastrointestinal disorders, respiratory conditions, neurological diseases, women’s healthcare and anti-infective treatments.

It has also strengthened its position in specialised healthcare through acquisitions and investments aimed at expanding its therapeutic portfolio.

Mankind Pharma operates 32 manufacturing facilities in India and maintains seven dedicated research and development facilities supported by more than 740 scientists.

Its pharmaceutical distribution network reaches more than five lakh doctors across urban and rural markets, supported by a field force exceeding 18,500 professionals.

The acquisition of Armed Cell Therapeutics marks a further step in the company’s transition towards a research-driven pharmaceutical business with participation in advanced biotechnology.

Rather than relying solely on established pharmaceutical formulations, the company is expanding into therapeutic platforms that require specialised scientific expertise and long-term research investment.

The investment also complements its broader efforts to strengthen capabilities in complex and chronic disease treatment.

Mankind Pharma Aims to Improve Access to Advanced Cancer Therapies

Mankind Pharma has identified innovation, scientific research and accessibility as important elements of its long-term pharmaceutical development strategy.

Commenting on the acquisition, Chief Operating Officer Arjun Juneja highlighted the company’s ambition to build a global pipeline of innovative therapies through partnerships with advanced research organisations.

He explained that the investment provides access to differentiated scientific platforms, experienced biotechnology leadership and opportunities to develop multiple next-generation CAR-T candidates.

The company’s long-term objective includes making transformative cancer therapies more accessible to patients in India and international markets.

This ambition is particularly relevant because advanced cell therapies currently require specialised manufacturing facilities, highly trained medical teams and substantial financial resources.

The development of innovative therapeutic platforms, alongside improvements in manufacturing and clinical delivery, could contribute to broader access over time.

Mankind Pharma’s experience in pharmaceutical manufacturing, distribution and commercial operations provides capabilities that may support the future development of advanced therapies.

The acquisition establishes a foundation for participation in CAR-T research, with future patient access dependent on successful clinical development, regulatory approvals and the establishment of appropriate treatment infrastructure.

India Strengthens Its Participation in Advanced Biotechnology

The acquisition reflects the growing international participation of Indian pharmaceutical companies in advanced biotechnology and innovative drug development.

India has established a strong pharmaceutical manufacturing base, particularly in generic medicines, vaccines and affordable healthcare products. Indian companies are increasingly expanding into complex biologics, specialised therapies and research-driven pharmaceutical technologies.

Cell and gene therapies represent an emerging area of medical innovation requiring expertise in molecular biology, genetic engineering, immunology, clinical research and specialised manufacturing.

India has already made progress in indigenous CAR-T technology development through collaborations involving academic institutions, hospitals and biotechnology companies.

The approval of NexCAR19, an indigenously developed CAR-T therapy, demonstrated the country’s growing capabilities in advanced cell-based cancer treatment.

International acquisitions and research partnerships can complement these domestic efforts by expanding access to specialised scientific platforms and experienced development teams.

Mankind Pharma’s investment in Armed Cell Therapeutics provides an example of an Indian pharmaceutical company participating directly in the development of next-generation cancer therapies through international biotechnology collaboration.

Such investments can strengthen connections between India’s pharmaceutical industry and global scientific research networks while supporting the development of expertise in emerging therapeutic technologies.

Acquisition Strengthens India–Europe Biotechnology Cooperation

The transaction also contributes to expanding industrial and research cooperation between India and Europe in the pharmaceutical and biotechnology sectors.

Armed Cell Therapeutics brings together biotechnology expertise from Belgium, the Netherlands and international research institutions, while Mankind Pharma contributes the resources and capabilities of an established Indian pharmaceutical company.

The partnership creates opportunities for cooperation in cell engineering, cancer immunotherapy, research management and future therapeutic development.

International biotechnology collaboration is particularly important in advanced treatment areas because research often requires specialised facilities, multidisciplinary scientific teams and access to different clinical and technological capabilities.

By investing in ACTx, Mankind Pharma is extending its international presence beyond conventional pharmaceutical manufacturing and commercial distribution.

The development strengthens the company’s participation in global innovation networks and supports its ambition to build a diversified pipeline of advanced therapeutic products.

Mankind Pharma Advances Towards Innovation-Led Cancer Treatment

Mankind Pharma’s proposed acquisition of a 70% stake in Armed Cell Therapeutics for €48 million marks an important development in the international expansion of India’s pharmaceutical industry.

The investment provides the company with majority ownership in a biotechnology enterprise developing next-generation CAR-T therapies for cancers including non-Hodgkin lymphoma and small-cell lung cancer.

ACTx’s research in armed CAR-T cells, multiple-antigen targeting and in vivo cell engineering offers access to emerging technologies intended to improve cancer treatment effectiveness and durability.

The transaction also strengthens Mankind Pharma’s long-term strategy of expanding from established pharmaceutical products into research-intensive and technologically advanced therapies.

With international scientific expertise and an established Indian pharmaceutical partner, Armed Cell Therapeutics will continue pursuing innovative approaches to cancer immunotherapy.

The partnership represents a step towards greater Indian participation in global biotechnology research and supports the long-term objective of developing advanced cancer treatments that can reach more patients in India and around the world.

---

References

1. Mankind Pharma Limited – Official Press Release, October 15, 2026: Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies
2. Mankind Pharma Limited – Stock Exchange Disclosure, October 15, 2026: Board Meeting Outcome and Approval of Investment in Armed Cell Therapeutics
3. Mankind Pharma Limited – Official Press Release, July 1, 2026: Mankind Pharma and Denovo Sciences Join Forces to Drive AI-Led Innovation in Drug Discovery
4. Mankind Pharma Limited: Official Corporate Website
5. Armed Cell Therapeutics: Official Corporate Website

---